277 related articles for article (PubMed ID: 8475497)
1. Strain differences in the response of Fischer 344 and Sprague-Dawley rats to monocrotaline induced pulmonary vascular disease.
Pan LC; Wilson DW; Segall HJ
Toxicology; 1993 Mar; 79(1):21-35. PubMed ID: 8475497
[TBL] [Abstract][Full Text] [Related]
2. COR pulmonale is caused by monocrotaline and dehydromonocrotaline, but not by glutathione or cysteine conjugates of dihydropyrrolizine.
Pan LC; Wilson DW; Lamé MW; Jones AD; Segall HJ
Toxicol Appl Pharmacol; 1993 Jan; 118(1):87-97. PubMed ID: 8430429
[TBL] [Abstract][Full Text] [Related]
3. Cellular fibronectin and von Willebrand factor concentrations in plasma of rats treated with monocrotaline pyrrole.
Schultze AE; Emeis JJ; Roth RA
Biochem Pharmacol; 1996 Jan; 51(2):187-91. PubMed ID: 8615888
[TBL] [Abstract][Full Text] [Related]
4. Bioactivation of monocrotaline by P-450 3A in rat liver.
Kasahara Y; Kiyatake K; Tatsumi K; Sugito K; Kakusaka I; Yamagata S; Ohmori S; Kitada M; Kuriyama T
J Cardiovasc Pharmacol; 1997 Jul; 30(1):124-9. PubMed ID: 9268231
[TBL] [Abstract][Full Text] [Related]
5. Chronic pulmonary hypertension--the monocrotaline model and involvement of the hemostatic system.
Schultze AE; Roth RA
J Toxicol Environ Health B Crit Rev; 1998; 1(4):271-346. PubMed ID: 9776954
[TBL] [Abstract][Full Text] [Related]
6. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats.
Tofovic SP; Salah EM; Mady HH; Jackson EK; Melhem MF
J Cardiovasc Pharmacol; 2005 Oct; 46(4):430-7. PubMed ID: 16160593
[TBL] [Abstract][Full Text] [Related]
7. Hypertrophy and prolonged DNA synthesis in smooth muscle cells characterize pulmonary arterial wall thickening after monocrotaline pyrrole administration to rats.
Lappin PB; Roth RA
Toxicol Pathol; 1997; 25(4):372-80. PubMed ID: 9280120
[TBL] [Abstract][Full Text] [Related]
8. Strain differences in pulmonary hypertensive response to monocrotaline alkaloid and the beneficial effect of oral magnesium treatment.
Mathew R; Altura BT; Altura BM
Magnesium; 1989; 8(2):110-6. PubMed ID: 2526910
[TBL] [Abstract][Full Text] [Related]
9. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension.
Hilliker KS; Bell TG; Lorimer D; Roth RA
Am J Physiol; 1984 Jun; 246(6 Pt 2):H747-53. PubMed ID: 6742140
[TBL] [Abstract][Full Text] [Related]
10. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
11. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.
Tofovic SP; Zhang X; Jackson EK; Dacic S; Petrusevska G
Vascul Pharmacol; 2006 Dec; 45(6):358-67. PubMed ID: 16872912
[TBL] [Abstract][Full Text] [Related]
12. Effects of monocrotaline pyrrole on cultured rat pulmonary endothelium.
Hoorn CM; Wagner JG; Roth RA
Toxicol Appl Pharmacol; 1993 Jun; 120(2):281-7. PubMed ID: 8511798
[TBL] [Abstract][Full Text] [Related]
13. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
14. Changes in alpha(1)-adrenergic vascular reactivity in monocrotaline-treated rats.
Dhein S; Giessler C; Heinroth-Hoffmann I; Leineweber K; Seyfarth T; Brodde OE
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):87-95. PubMed ID: 11819025
[TBL] [Abstract][Full Text] [Related]
15. Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole.
Reindel JF; Ganey PE; Wagner JG; Slocombe RF; Roth RA
Toxicol Appl Pharmacol; 1990 Nov; 106(2):179-200. PubMed ID: 2256110
[TBL] [Abstract][Full Text] [Related]
16. The effect of immunosuppressants and adoptive transfer in monocrotaline pyrrole pneumotoxicity.
Bruner LH; Bull RW; Roth RA
Toxicol Appl Pharmacol; 1987 Oct; 91(1):1-12. PubMed ID: 3672514
[TBL] [Abstract][Full Text] [Related]
17. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats.
Horstman DJ; Frank DU; Rich GF
Anesth Analg; 1998 Jan; 86(1):74-81. PubMed ID: 9428855
[TBL] [Abstract][Full Text] [Related]
18. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
[TBL] [Abstract][Full Text] [Related]
19. [Role of peptide leukotrienes in monocrotaline-induced lung disease].
Ono S; Noda M; Tanita T; Hoshikawa Y; Tabata T; Ueda S; Nishimura T; Ashino Y; Koike K; Fujimura S
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Dec; 33(12):1415-1420. PubMed ID: 8821996
[TBL] [Abstract][Full Text] [Related]
20. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats.
White SM; Wagner JG; Roth RA
Toxicol Appl Pharmacol; 1989 Jun; 99(2):302-13. PubMed ID: 2734793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
